Life value

STELLAPHARM was born to care and protect patient’s health, to help enhancing their lives and living longer. Your health, for today and for future.


As one of seven generic drug manufacturers selected by MPP and becoming a sub-licensee of Shionogi – a Japanese pharmaceutical manufacturer to produce of XOCOVA™ drug, generic version. Stellapharm is honored and proud to have contributed to repelling the COVID-19 pandemic with drugs. This is the third oral product in the world to be recognized


On February 21, 2022, Stellapharm officially signed a contract with MPP (Medicines Patent Pool), a UNITED NATIONS-backed public health organization to become the only manufacturer in Vietnam allowed to produce a generic version of Pfizer’s oral COVID-19 treatment, nirmatrelvir, which will be co-packaged with ritonavir, under the voluntary licensing agreement between Pfizer and the MPP.

Drug Administration grants licences for first three made-in-Việt Nam Molnupiravir products

HÀ NỘI — The Drug Administration of Việt Nam under the Ministry of Health has issued the list of three COVID-19 treatment drugs produced in Việt Nam that contain the antiviral ingredient Molnupiravir, which have been granted certificates of registration for conditional use. The three products – Molravir 400mg produced by Boston Việt Nam Pharma (based in

27 generic manufacturers sign agreements with MPP to produce low-cost versions of COVID-19 antiviral medication molnupiravir for supply in 105 low- and-middle-income countries

20 January 2022 Geneva – The Medicines Patent Pool (MPP) announced today that it has signed agreements with 27 generic manufacturing companies for the manufacturing of the oral COVID-19 antiviral medication molnupiravir and supply in 105 low- and-middle-income countries (LMICs). The sublicence agreements are the result of the voluntary licensing agreement signed by MPP and


On January 10, 2022, Stellapharm officially signed an agreement with MPP (Medicines Patent Pool), a UNITED NATIONS-backed public health organization to become the only manufacturer in Vietnam allowed to produce the COVID-19 treatment molnupiravir under the "Voluntary Licensing" program for MSD, a trade name of Merck & Co., Inc., Kenilworth, NJ, USA.

FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults

in December 23, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Merck’s molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom

Japan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill

Nov 10 (Reuters) – Merck & Co Inc (MRK.N) and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill molnupiravir. Countries have rushed to sign deals to buy molnupiravir, since data last month showed that when given early in the illness

Merck expects Covid pill to reach rich and poor countries simultaneously

Washington (AFP) – US pharmaceutical giant Merck has vowed to avoid the pitfalls of the global Covid vaccine rollout by ensuring its new anti-coronavirus pill is made available in wealthy and poor countries at almost the same time. Paul Schaper, the company’s executive director of global public policy, told AFP that Merck began working on

India could approve Covid pill in matter of days

Molnupiravir can be taken as a pill instead of injection or intravenous administration. Antiviral drug Molnupiravir, used for treating mild to moderate Covid-19 infections, is set to enter the Indian markets within days, an official confirmed on Wednesday. Manufactured by US drug companies Merck, Sharp and Dohme, Molnupiravir is among the first proven drugs to

First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA

The antiviral was found to be safe and effective following a stringent review of the available evidence. The antiviral Lagevrio (molnupiravir) is safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease, the Medicines and Healthcare products Regulatory

KHMER Ministry of Health approves use of Molnupiravir to treat COVID-19 in ’emergencies’

The Ministry of Health has authorized the use of COVID-19 drug Molnupiravir for emergency conditions. The Ministry said that Molnupiravir is an oral and oral anti-COVID pill that is safe and highly effective for treating COVID-19. Molnupiravir is manufactured by Mylan Laboratories Limited, based in India. The Ministry of Health states that the conditions for

Merck says research shows its COVID-19 pill works against variants

Sept 29 (Reuters) – Laboratory studies show that Merck & Co’s (MRK.N) experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta, the company said on Wednesday. Since molnupiravir does not target the spike protein of the virus – the target of

Countries in Asia are placing orders for a new drug to treat coronavirus. Poorer nations could miss out again

(CNN)_During the global scramble to secure vaccines, many countries in Asia-Pacific were slow off the mark. This time, they’re not making the same mistake.Countries around the region are rushing to place orders for the latest weapon against Covid-19: an antiviral pill that isn’t even authorized for use yet. Molnupiravir — produced by US pharmaceutical company

U.S. government to buy $1 billion more worth of Merck's COVID-19 pill

(Reuters) – The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc and partner Ridgeback Biotherapeutics, the companies said on Tuesday. The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.

New antiviral pill halves risk of COVID-19 hospitalization, Merck says

In a late-stage clinical trial, a new antiviral pill halved the chance that patients diagnosed with COVID-19 would end up in the hospital or die from the disease, the drugmaker Merck announced Friday (Oct. 1). The drug, called molnupiravir, was developed by Merck and Ridgeback Biotherapeutics and could be the first oral medication specifically approved

Will New Covid Treatments Be as Elusive for Poor Countries as Vaccines?

By Stephanie NolenOct. 17, 2021 Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs. Nearly a year after the first Covid-19 vaccination campaigns began, the vast majority of the shots have gone to people in wealthy nations, with no clear

Merck says its new Covid pill reduces the risk of hospitalization, death by half for some patients

Merck and Ridgeback Biotherapeutics said Friday they’ve developed a drug that reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases of Covid. The companies plan to seek emergency authorization for the antiviral Covid treatment after the medicine showed “compelling results” in clinical trials. The drug, molnupiravir, is

Molnupiravir – an oral antiviral treatment for COVID-19

A novel coronavirus, originally identified in Wuhan City, China, was reported to the World Health Organization on 31 December 2019, and the associated disease has subsequently become a worldwide pandemic. An effective antiviral therapeutic has since been intensively sought. Coronaviruses use an RNA-dependent RNA polymerase (RdRp) for the replication and transcription of their RNA genome.

An oral pill for COVID-19? Molnupiravir shows promise

[Updated to July 2021] The results of the trial demonstrate the safety, tolerability, and antiviral efficacy of molnupiravir to reduce replication of SARS-CoV-2 and accelerate clearance of infectious virus and support ongoing trials of molnupiravir to prevent progression of COVID-19 and eliminate onward transmission of SARS-CoV-2. After more than one year into the coronavirus disease

Ho Chi Minh City uses Molnupiravir for treating Covid-19 patients at home

According to Minister of Health Nguyen Thanh Long, the Ministry of Health and the Department of Health of Ho Chi Minh City start using the experimental antiviral drug Molnupiravir to treat Covid-19 patients with mild-symptom from August 27, 2021. He said this while inspecting the Covid-19 prevention and control task in Ho Chi Minh City’s

Stellapharm supports European partners in Covid-19 pandemic

Since the beginning of February this year, many consignments of Stella's pharmaceutical products with a total of nearly 200 million units have been urgently exported by air to markets in Germany, France, Austria, Belgium, Ireland, etc.

Company Name Change

STADA - VN JOINT VENTURE CO., LTD. officially changed its name to STELLAPHARM J.V. CO., LTD. since 16 August 2019.

We produce a wide
range of prescription
and non-prescription drugs

Castella 90

Castella 90 is co-administered with acetylsalicylic in the prevention of atherothrombotic events in adult patients with acute coronary syndromes and with history of myocardial infarction and a high risk of developing an atherothrombotic event.


Eperistad is effective in improving myotonic symptoms such as stiffness of shoulders, cervical pain, muscle contraction type headache, dizziness, lower back pain and rigidity of extremeties which may accompany encephalomyelopathies, cervical syndrome, periarthritis of the shoulder or lumbago.

Ezecept 20/10

Ezecept 20/10 containing ezetimibe and atorvastatin, is a lipid-lowering agent that selectively inhibits the intestinal absorption of cholesterol and related phytosterols and inhibits endogenous cholesterol synthesis.

Gliptinestad 50

Gliptinestad (Sitagliptin 50 mg) is indicated to improve glycaemic control in adult patients with type 2 diabetes mellitus.


Helix STELLA containing dried ivy leaf extract helps relieve cough and reduce phlegm.


Helix STELLA FORTE containing dried ivy leaf extract (Hedera helix L.) helps relieve cough and reduce phlegm.

Lorastad D Syrup

Lorastad D Syrup is indicated for the relief of symptoms associated with allergic rhinitis and urticaria.

Amioxilto 200

Amiodarone is an antiarrhythmic drug used to treat and prevent certain types of arrhythmias. These arrhythmias include ventricular tachycardia, ventricular fibrillation, and wide QRS tachycardia, as well as atrial fibrillation and paroxysmal supraventricular tachycardia. However, evidence in cardiac arrest is limited.

Partamol eff.

Partamol eff. is used for treatment of mild to moderate pain and fever, especially in patients in whom salicylates are contraindicated or not tolerated.


Partamol-Cafein is fixed-combination of paracetamol and caffeine that is indicated for treatment of most painful and febrile conditions, for example, headache, including migraine, backache, toothache.....

Partamol C

Partamol C is fixed-combination of paracetamol and vitamin C that is indicated for treatment of mild to moderate pain and fever.

Molnupiravir STELLA 400 mg

Molnupiravir is indicated for the treatment of mild to moderate COVID-19 disease in adults with a positive diagnostic test for SARS-CoV-2 and with at least one risk factor for severe disease progression.

Flustad 75

Flustad 75 is an antiviral drug for systemic use indicated for treatment and prevention of influenza in adults and children (including full term neonates) following contact with an infected person influenza. Flustad 75 is not a substitute for influenza vaccination.

Ribastad 200

Ribastad 200 is indicated for the treatment of hepatitis C, haemorrhagic fevers.

Tefostad T300

Tefostad T300 is used in conjunction with other antiretroviral agents (should not be used alone) in the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults, post-exposure prophylaxis of HIV infection and in treatment of chronic hepatitis B in adults.


Lesovir is a fixed-dose combination of ledipasvir and sofosbuvir which are direct-acting antiviral agents against the hepatitis C virus.

Lamone 100

Lamone 100 is lamivudine, an active against virus type 1 and type 2 (HIV-1, HIV-2) and inhibitory activity against human hepatitis B virus in chronic patients.

Linestad 600

Linestad 600 is indicated for treatment of pneumonia and skin and soft tissue infections.

Xelostad 10

Xelostad 10 is used for prevention of venous thromboembolism (VTE) in adult patients, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.


Statripsine is used for treatment of post traumatic, post-operative oedema, burn.


Bicimax is used for supplementation of deficiencies of the vitamins B complex, vitamin C, calcium and magnesium: e.g., prolonged stress, prolonged infection and fever, intestinal diseases, gastrectomy, alcohol abuse, ...


Pravitce contains calcium and vitamin C. Its main use is to supplement these two substances for people suffering from nutritional deficiencies, during pregnancy, lactation, adolescents during growth, and the elderly.

Predstad 20

Treatment and/or suppression of inflammatory and allergic disorders.


Bamstad is indicated for management of asthma, bronchospasm and/or reversible airways obstruction in adults.


Stadeltine is for the relief of nasal and ocular symptoms of seasonal, perennial allergic rhinitis and chronic idiopathic urticaria.

Mopristad 5

Mopristad 5 is indicated for the treatment of gastrointestinal symptoms (heartburn, nausea/vomiting) associated with functional dyspepsia (chronic gastritis).


Alumastad contains dried aluminum hydroxide gel and magnesium hydroxide which are antacids pain reliever and indigestion discomfort by neutralizing acid, reducing the excess acidity in the stomach.

Zecein 80

Zecein 80 belongs to the group of smooth muscle spasmolytic agent indicated for treatment of pain syndromes of various organs: gastrointestinal, biliary, urogenital and vascular systems.

Shaping Tomorrow

We are embracing technology and partnership to leverage that strengthen to advance research, develop and produce new generic drugs.